S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NYSE:IKT

Inhibikase Therapeutics - IKT Stock Forecast, Price & News

$0.89
+0.02 (+2.30%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.79
$0.95
50-Day Range
$0.74
$1.02
52-Week Range
$0.60
$2.54
Volume
288,254 shs
Average Volume
125,673 shs
Market Capitalization
$22.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IKT stock logo

About Inhibikase Therapeutics (NYSE:IKT) Stock

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Inhibikase Therapeutics Trading Down 3.9 %

Inhibikase Therapeutics stock opened at $0.86 on Thursday. The firm's 50 day simple moving average is $0.86 and its 200 day simple moving average is $1.06. The firm has a market capitalization of $21.81 million, a PE ratio of -1.11 and a beta of 1.47. Inhibikase Therapeutics has a 1-year low of $0.60 and a 1-year high of $2.54.

Inhibikase Therapeutics (NYSE:IKT - Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter. The company had revenue of $0.05 million during the quarter. Inhibikase Therapeutics had a negative return on equity of 41.29% and a negative net margin of 964.94%.

Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IKT Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Inhibikase Therapeutics, Inc. (IKT)
Stop Day Trading - More Here
Jeff Clark - "I Never Worry About Where The Market Is Headed. I Only Trade One Stock". Learn More. pixel
Vetoquinol: Q1 2022 Sales: €135M
See More Headlines
Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IKT Company Calendar

Last Earnings
5/16/2022
Today
8/11/2022
Next Earnings (Confirmed)
8/12/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-14,790,000.00
Net Margins
-964.94%
Pretax Margin
-964.94%

Debt

Sales & Book Value

Annual Sales
$3.10 million
Book Value
$1.53 per share

Miscellaneous

Free Float
11,150,000
Market Cap
$22.40 million
Optionable
Not Optionable
Beta
1.47














IKT Stock - Frequently Asked Questions

How have IKT shares performed in 2022?

Inhibikase Therapeutics' stock was trading at $1.47 at the beginning of 2022. Since then, IKT stock has decreased by 40.1% and is now trading at $0.88.
View the best growth stocks for 2022 here
.

When is Inhibikase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our IKT earnings forecast
.

How can I listen to Inhibikase Therapeutics' earnings call?

Inhibikase Therapeutics will be holding an earnings conference call on Monday, August 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) posted its earnings results on Monday, May, 16th. The company reported ($0.18) EPS for the quarter. The business earned $0.05 million during the quarter. Inhibikase Therapeutics had a negative trailing twelve-month return on equity of 41.29% and a negative net margin of 964.94%.

When did Inhibikase Therapeutics IPO?

(IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Inhibikase Therapeutics' stock symbol?

Inhibikase Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "IKT."

Who are Inhibikase Therapeutics' major shareholders?

Inhibikase Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Koshinski Asset Management Inc. (0.26%). Insiders that own company stock include Joseph Frattaroli and Milton H Werner.
View institutional ownership trends
.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibikase Therapeutics' stock price today?

One share of IKT stock can currently be purchased for approximately $0.88.

How much money does Inhibikase Therapeutics make?

Inhibikase Therapeutics (NYSE:IKT) has a market capitalization of $22.20 million and generates $3.10 million in revenue each year. The company earns $-14,790,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Inhibikase Therapeutics?

The official website for the company is www.inhibikase.com. The company can be reached via phone at 678-392-3419 or via email at alex.lobo@sternir.com.

This page (NYSE:IKT) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.